SEATTLE--(BUSINESS WIRE)--Dec. 23, 2014--
Juno Therapeutics, Inc. (NASDAQ:JUNO) today announced the closing of its
initial public offering of 12.7 million shares of common stock at a
price to the public of $24.00 per share, which includes the exercise in
full by the underwriters of the offering of their option to purchase 1.7
Morgan Stanley & Co. LLC, J.P. Morgan Securities LLC, and Goldman, Sachs
& Co. are acting as lead book-running managers for the offering. Leerink
Partners LLC is acting as a co-manager.
Copies of the final prospectus relating to this offering may be obtained
from Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180
Varick Street, 2nd Floor, New York, NY 10014; J.P. Morgan Securities
LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue,
Edgewood, NY 11717, or by telephone at (866) 803-9204; and Goldman,
Sachs & Co. by mail at 200 West Street, New York, New York 10282,
Attention: Prospectus Department, by calling toll-free (866) 471-2526,
or by e-mailing email@example.com.
A registration statement relating to these securities has been declared
effective by the Securities and Exchange Commission on December 18,
2014. Copies of the registration statement, as amended, can be accessed
through the SEC's website at www.sec.gov.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of these
securities in any state or jurisdiction in which such offer,
solicitation, or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
Juno Therapeutics, Inc. is a biopharmaceutical company developing
cell-based cancer immunotherapies based on chimeric antigen receptor and
high-affinity T cell receptor technologies to genetically engineer T
cells to recognize and kill cancer cells.
Source: Juno Therapeutics, Inc.
David Walsey, 858-617-0772
Andreas Marathovouniotis, 212-301-7174